Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on the development of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with what we believe are innovative mechanisms of action. Our executive management team includes globally recognized specialists in central nervous system diseases addressing significant unmet medical needs. Source
No articles found.
Correvio has two marketed, in-hospital, cardiology products: BRINAVESSÂŽ (vernakal...
Correvio has two marketed, in-hospital, cardiol...
For more than 40 years, IntriCon has been meeting the rising demand for smaller, p...
For more than 40 years, IntriCon has been meeti...
Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on o...
Immuron Ltd is a publicly listed Australian bio...
Avenue Therapeutics, Inc., a Fortress Biotech (NASDAQ: FBIO) Company, is a special...
Avenue Therapeutics, Inc., a Fortress Biotech (...
PTC is a science-led, global biopharmaceutical company focused on the discovery, d...
PTC is a science-led, global biopharmaceutical ...
Sutro Biopharma, located in South San Francisco, is a clinical-stage drug discover...
Sutro Biopharma, located in South San Francisco...
Join the National Investor Network and get the latest information with your interests in mind.